Polyrizon

Company Overview

Snapshot

Founded in March 2020 by Tomer Izraeli, Polyrizon operates with 1–10 employees and has raised a total of $27.03 million across 9 funding rounds. The company went public on NASDAQ in October 2024.

Business overview

Polyrizon is a biotechnology company specializing in the development and commercialization of innovative intranasal products. The company's core technologies include the Capture & Contain (C&C) platform, a natural 3D polymeric network designed to create a physical barrier against airborne contaminants like allergens, viruses, and molds, and the Trap & Target (T&T) platform, a drug delivery system engineered for extended residence time and targeted delivery of medicines to mucosal tissue. Polyrizon operates within the Health Tech & Life Sciences sector, serving markets related to pharmaceuticals and medical biotechnology.

Strategic signal

In May 2026, Polyrizon announced a U.S. patent expansion for its intranasal drug delivery platform, followed by securing its first U.S. clinical site for the NASARIX™ Allergy Blocker clinical trial. This indicates significant progress in validating and commercializing its core technology, signaling to investors a strong forward trajectory in product development and market entry for its allergy treatment solutions.

Company Intelligence Q&A

What was a significant recent development regarding Polyrizon's intellectual property?

In May 2026, Polyrizon announced a U.S. patent expansion for its intranasal drug delivery platform, strengthening its proprietary technology in the market.

What is Polyrizon's progress towards human clinical trials for its allergy blocker?

In May 2026, Polyrizon advanced towards human clinical trials by securing its first U.S. clinical site for the NASARIX™ Allergy Blocker clinical trial, indicating a move from preclinical to clinical development.

What was a key manufacturing milestone for Polyrizon's clinical development program?

In March 2026, Polyrizon announced the GMP manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for its planned U.S. clinical study, a critical step for clinical development.

What strategic agreement did Polyrizon sign in March 2026?

In March 2026, Polyrizon signed an agreement with a leading global Preclinical CRO as part of its clinical development program, aiming to accelerate its product pipeline.

What was a recent financial event for Polyrizon?

In April 2026, Polyrizon announced the closing of a $3.5 million registered direct and private placement, contributing to its total capital raised of $27.03 million.